Clinical trials: sponsored by Canadian Cancer Trials Group
Alveolar Soft Part Sarcoma, Renal Cell Carcinoma
GCAR1, a Chimeric Antigen Receptor (CAR) T-CELL Therapy for Relapsed/Refractory GPNMB-Expressing Solid Tumours
Only enrolling in Canada. The purpose of this study is to identify the highest dose of GCAR1, a chimeric antigen receptor (CAR-T) cell therapy, that can be tolerated without causing very severe side effects, and to see what…
- Conditions
- Alveolar Soft Part Sarcoma, Renal Cell Carcinoma, Triple Negative Breast Cancer
- Trial name
- NCT07297667
- Testing
- Fludarabine, Cyclophosphamide, GCAR1
- Where
- 4 sites in Canada
- Volunteers
- 30 people
- Sponsor
- Canadian Cancer Trials Group
Lymphoma
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
The purpose of this study is to find out what effects new combinations of treatment will have this disease. New promising treatment strategies will be added to this study as they are available to be compared against the standard…
- Trial name
- NCT02436707
- Testing
- Ibrutinib, Rituximab, Gemcitabine
- Where
- 11 sites in Canada
- Volunteers
- 129 people
- Sponsor
- Canadian Cancer Trials Group
Advanced Rare Tumours
A Phase II Study of Sunitinib or Temsirolimus in Patients With Advanced Rare Tumours
This research is being done because there is no treatment that will cure this type of cancer. Although some types of chemotherapy can cause this cancer to shrink for a time, better options are needed.
- Trial name
- NCT01396408
- Testing
- Sunitinib, Temsirolimus
- Where
- 17 sites in Canada
- Volunteers
- 137 people
- Sponsor
- Canadian Cancer Trials Group
Lymphoma, B-Cell
Phase I Master Protocol of Novel Combination Therapy for Patients With Relapsed or Refractory Aggressive B-Cell Lymphoma
The purpose of this study is to find the highest dose of a new drug, in combination with standard drugs, which can be tolerated without causing very severe side effects.
- Trial name
- NCT04161248
- Testing
- Venetoclax, Rituximab Injection, Rituximab SC
- Where
- 4 sites in Canada
- Volunteers
- 40 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Liquid-biopsy Informed Platform Trial to Evaluate CDK4/6-inhibitor Resistant ER+/HER2- Metastatic Breast Cancer
This study is being done to answer the following question: Can testing breast cancer for DNA abnormalities or "biomarkers" help predict which patients are most likely to be helped by certain treatments? The pre-study screening is…
- Trial name
- NCT05601440
- Testing
- RP-6306, Gemcitabine, Observation
- Where
- 10 sites in Canada
- Volunteers
- 484 people
- Sponsor
- Canadian Cancer Trials Group
Advanced Rare Tumours
Durvalumab and Tremelimumab in Patients With Advanced Rare Tumours
The standard or usual treatment for this disease may be chemotherapy or other types of treatment to slow the spread of the disease and relieve some symptoms of this cancer.
- Trial name
- NCT02879162
- Testing
- Durvalumab, Tremelimumab
- Where
- 13 sites in Canada
- Volunteers
- 140 people
- Sponsor
- Canadian Cancer Trials Group
Breast Cancer
Letrozole in Breast Cancer Who Have Received 5 Years of Aromatase Inhibitor Therapy
RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using letrozole may fight breast cancer by lowering the amount of estrogen the body makes.
- Trial name
- NCT00754845
- Testing
- letrozole
- Where
- 43 sites in Canada, United Kingdom
- Volunteers
- 1,918 people
- Sponsor
- Canadian Cancer Trials Group
Recurrent Lymphoma, Refractory Lymphoma
Vinblastine and Temsirolimus in Pediatrics With Recurrent or Refractory Lymphoma or Solid Tumours Including CNS Tumours
The purpose of this study is to determine the best dose of vinblastine that can be given with a new drug, temsirolimus.
- Conditions
- Recurrent Lymphoma, Refractory Lymphoma, Solid Tumours, Central Nervous System
- Trial name
- NCT02343718
- Testing
- Vinblastine, Temsirolimus
- Where
- 6 sites in Canada
- Volunteers
- 7 people
- Sponsor
- Canadian Cancer Trials Group